Company Overview More
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL. The company also develops ALLO-501, an anti-CD19 allogeneic CAR T cell product candidate that is in Phase I clinical trial for the treatment of R/R non-Hodgkin lymphoma; and ALLO-501A, which is in Phase I/II clinical trial for the treatment R/R large B-cell lymphoma or transformed follicular lymphoma. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for treating R/R multiple myeloma; ALLO-819, an allogeneic CAR T cell product candidates for the treatment of acute myeloid leukemia; ALLO-605, an allogeneic CAR T cell product candidate for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; and DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc., as well as clinical trial collaboration agreement with SpringWorks Therapeutics, Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates. The company was founded in 2017 and is headquartered in South San Francisco, California.
CEO: --
Market: NASDAQ
Futu Hot List
USHKCN
Trade HeatSearch HeatNews Heat
SymbolLatest Price% Chg

Loading...

ALLO Allogene Therapeutics Inc

16.890+0.950+5.96%
Trading Session 10/28 14:45 ET
High
16.900
Open
15.940
Turnover
11.70M
Low
15.880
Prev.Close
15.940
Volume
706.38K
Market Cap
2.40B
P/E(TTM)
Loss
52Wk High
39.118
Shares
142.18M
P/E
Loss
52Wk Low
12.900
H Mkt Cap
1.24B
Bid-Ask Ratio
75.00%
Historical High
55.000
H Shares
73.67M
Vol. Ratio
0.83
Historical Low
12.900
Dividend TTM
--
Div Yield TTM
45
P/B
2.35
Dividend LFY
--
Div Yield LFY
266.43%
Turnover Ratio
0.96%
Amplitude
6.40%
Avg Price
16.556
Min Trading Unit
1
Float Market Cap
1.24B
Bid-Ask Ratio
75.00%
Historical High
55.000
Float
73.67M
Vol. Ratio
0.83
Historical Low
12.900
Dividend TTM
--
P/B
2.35
Dividend LFY
--
Turnover Ratio
0.96%
Amplitude
6.40%
Avg Price
16.556
Min Trading Unit
1
Price Forecast

Loading...

News